|
US8597910B1
(en)
|
1985-04-11 |
2013-12-03 |
Children's Medical Center Corporation |
DNA encoding Von Willebrand Factor (VWF) and methods and cells for producing VFW, and VFW produced by the DNA, methods and cells
|
|
US5198349A
(en)
*
|
1986-01-03 |
1993-03-30 |
Genetics Institute, Inc. |
Method for producing factor VIII:C and analogs
|
|
US5451521A
(en)
*
|
1986-05-29 |
1995-09-19 |
Genetics Institute, Inc. |
Procoagulant proteins
|
|
US5576194A
(en)
*
|
1986-07-11 |
1996-11-19 |
Bayer Corporation |
Recombinant protein production
|
|
GR871029B
(en)
|
1986-07-14 |
1987-11-02 |
Genetics Inst |
Novel osteoinductive factors
|
|
WO1988005825A1
(en)
*
|
1987-01-30 |
1988-08-11 |
Biogen N.V. |
A method for producing factor viii in high yield
|
|
CA1331157C
(en)
*
|
1987-04-06 |
1994-08-02 |
Randal J. Kaufman |
Method for producing factor viii:c-type proteins
|
|
US5043429B1
(en)
*
|
1987-05-01 |
1997-10-14 |
Scripps Research Inst |
Protein fragments containing factor VIII binding domain of von willebrand factor
|
|
JPH0387173A
(ja)
*
|
1987-09-10 |
1991-04-11 |
Teijin Ltd |
ヒト活性化天然型ファクター8cの製造方法及びそれに用いる形質転換体
|
|
CA1340740C
(en)
*
|
1987-12-08 |
1999-09-14 |
Eileen R. Mulvihill |
Co-expression in eukaryotic cells
|
|
US5648254A
(en)
*
|
1988-01-15 |
1997-07-15 |
Zymogenetics, Inc. |
Co-expression in eukaryotic cells
|
|
US5811523A
(en)
|
1988-11-10 |
1998-09-22 |
Trinchieri; Giorgio |
Antibodies to natural killer stimulatory factor
|
|
DE69012601T2
(de)
*
|
1989-02-02 |
1995-01-19 |
Joel S Greenberger |
Gentherapie durch stützgewebebezügliche Zellen.
|
|
US7247475B2
(en)
|
1989-07-28 |
2007-07-24 |
Wyeth |
Method for producing monoclonal antibodies
|
|
US6475787B1
(en)
|
1989-07-28 |
2002-11-05 |
Wyeth |
Method for producing monoclonal antibodies
|
|
SE465222C5
(sv)
*
|
1989-12-15 |
1998-02-10 |
Pharmacia & Upjohn Ab |
Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
|
|
FR2657884B1
(fr)
|
1990-02-05 |
1994-09-02 |
Tm Innovation |
Procede pour la preparation du facteur viii humain et d'analogues du facteur viii.
|
|
US5661008A
(en)
*
|
1991-03-15 |
1997-08-26 |
Kabi Pharmacia Ab |
Recombinant human factor VIII derivatives
|
|
US5371198A
(en)
*
|
1991-12-16 |
1994-12-06 |
Novo Nordisk A/S |
Method for protection of proteolysis-susceptible protein during protein production in a fluid medium
|
|
DK53792D0
(da)
*
|
1992-04-24 |
1992-04-24 |
Novo Nordisk As |
Fremgangsmaade til fremstilling af proteiner
|
|
US5563045A
(en)
|
1992-11-13 |
1996-10-08 |
Genetics Institute, Inc. |
Chimeric procoagulant proteins
|
|
US5952198A
(en)
*
|
1995-05-04 |
1999-09-14 |
Bayer Corporation |
Production of recombinant Factor VIII in the presence of liposome-like substances of mixed composition
|
|
US5744326A
(en)
*
|
1996-03-11 |
1998-04-28 |
The Immune Response Corporation |
Use of viral CIS-acting post-transcriptional regulatory sequences to increase expression of intronless genes containing near-consensus splice sites
|
|
US8183344B2
(en)
|
1996-04-24 |
2012-05-22 |
University Of Michigan |
Inactivation resistant factor VIII
|
|
PT1754718E
(pt)
|
1996-04-24 |
2011-07-13 |
Univ Michigan |
Factor viii resistente à inactivação
|
|
WO1998013387A1
(en)
|
1996-09-24 |
1998-04-02 |
The Procter & Gamble Company |
Stabilized proteinaceous protease inhibitors and variants thereof
|
|
ES2182501T3
(es)
|
1998-03-12 |
2003-03-01 |
Inst Genetics Llc |
Metodos mejorados para producir proteinas del factor viii.
|
|
US7820796B2
(en)
|
1998-03-12 |
2010-10-26 |
Genetics Institute, Llc. |
Methods for producing Factor VIII proteins
|
|
EP1038959A1
(en)
|
1999-03-17 |
2000-09-27 |
Aventis Behring Gesellschaft mit beschränkter Haftung |
Factor VIII without B-domain, comprising one or more insertions of a truncated intron I of factor IX
|
|
KR100581574B1
(ko)
*
|
2000-03-22 |
2006-05-22 |
옥타게네 게엠베하 |
인간 세포주 내 재조합 혈액 응고 인자의 제조
|
|
US7615622B2
(en)
|
2001-01-12 |
2009-11-10 |
University Of Maryland, Baltimore |
Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor VIII
|
|
EP1233064A1
(en)
|
2001-02-09 |
2002-08-21 |
Aventis Behring Gesellschaft mit beschränkter Haftung |
Modified factor VIII cDNA and its use for the production of factor VIII
|
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
|
US7211559B2
(en)
|
2003-10-31 |
2007-05-01 |
University Of Maryland, Baltimore |
Factor VIII compositions and methods
|
|
EP1707634A1
(en)
|
2005-03-29 |
2006-10-04 |
Octapharma AG |
Method for isolation of recombinantly produced proteins
|
|
EP1739179A1
(en)
|
2005-06-30 |
2007-01-03 |
Octapharma AG |
Serum-free stable transfection and production of recombinant human proteins in human cell lines
|
|
US7855279B2
(en)
|
2005-09-27 |
2010-12-21 |
Amunix Operating, Inc. |
Unstructured recombinant polymers and uses thereof
|
|
CA2656558A1
(en)
|
2006-06-30 |
2008-01-10 |
The Regents Of The University Of Michigan |
Method of producing factor viii proteins by recombinant methods
|
|
EP1988101A1
(en)
|
2007-05-04 |
2008-11-05 |
Novo Nordisk A/S |
Improvement of factor VIII polypeptide titers in cell cultures
|
|
CA2748314C
(en)
|
2009-02-03 |
2018-10-02 |
Amunix Operating Inc. |
Extended recombinant polypeptides and compositions comprising same
|
|
AU2010290131C1
(en)
|
2009-08-24 |
2015-12-03 |
Amunix Operating Inc. |
Coagulation factor VII compositions and methods of making and using same
|
|
PL3326643T3
(pl)
|
2009-12-06 |
2021-10-25 |
Bioverativ Therapeutics Inc. |
Chimeryczne i hybrydowe polipeptydy czynnika VIII-FC oraz sposoby ich zastosowania
|
|
WO2011095604A1
(en)
|
2010-02-04 |
2011-08-11 |
Octapharma Biopharmaceuticals Gmbh |
Half-life prolongation of proteins
|
|
SG10201505217WA
(en)
|
2010-07-09 |
2015-08-28 |
Biogen Hemophilia Inc |
Chimeric clotting factors
|
|
EP2591101B1
(en)
|
2010-07-09 |
2018-11-07 |
Bioverativ Therapeutics Inc. |
Systems for factor viii processing and methods thereof
|
|
CN107190034A
(zh)
|
2010-10-05 |
2017-09-22 |
诺沃—诺迪斯克保健股份有限公司 |
生产蛋白质的方法
|
|
CA2838833A1
(en)
|
2011-06-10 |
2012-12-13 |
Biogen Idec Ma Inc. |
Pro-coagulant compounds and methods of use thereof
|
|
CN103796670A
(zh)
|
2011-07-08 |
2014-05-14 |
比奥根艾迪克依蒙菲利亚公司 |
因子viii嵌合和杂合多肽及其使用方法
|
|
WO2013016454A1
(en)
|
2011-07-25 |
2013-01-31 |
Biogen Idec Hemophilia Inc. |
Assays to monitor bleeding disorders
|
|
EP3970737A1
(en)
|
2012-01-12 |
2022-03-23 |
Bioverativ Therapeutics Inc. |
Reducing immunogenicity against factor viii in individuals undergoing factor viii therapy
|
|
DK2804623T3
(da)
|
2012-01-12 |
2019-11-11 |
Bioverativ Therapeutics Inc |
Kimære faktor viii-polypeptider og anvendelser deraf
|
|
BR112014020694A2
(pt)
|
2012-02-15 |
2018-05-08 |
Amunix Operating Inc. |
proteína de fusão do fator viii compreendendo polipeptídeo do fator viii fusionado a polipeptí-deo recombinante estendido (xten) e seu método de fabricação, ácido nucleico, vetores, célula hospedeira, bem como composição farmacêutica e seu uso no tratamento de coagulopatia, episódio de hemorragia e hemofilia a
|
|
CA2864126A1
(en)
|
2012-02-15 |
2013-08-22 |
Biogen Idec Ma Inc. |
Recombinant factor viii proteins
|
|
EP2858659B1
(en)
|
2012-06-08 |
2019-12-25 |
Bioverativ Therapeutics Inc. |
Procoagulant compounds
|
|
JP2015525222A
(ja)
|
2012-06-08 |
2015-09-03 |
バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. |
キメラ性凝固因子
|
|
EP3404105A1
(en)
|
2012-07-06 |
2018-11-21 |
Bioverativ Therapeutics Inc. |
Cell line expressing single chain factor viii polypeptides and uses thereof
|
|
HRP20200007T1
(hr)
|
2012-07-11 |
2020-03-20 |
Bioverativ Therapeutics Inc. |
Kompleks proteina faktora viii s xten i von willebrandovim faktorom, te njegova uporaba
|
|
US10001495B2
(en)
|
2012-07-25 |
2018-06-19 |
Bioverativ Therapeutics Inc. |
Blood factor monitoring assay and uses thereof
|
|
CA2888806A1
(en)
|
2012-10-18 |
2014-04-24 |
Biogen Idec Ma Inc. |
Methods of using a fixed dose of a clotting factor
|
|
EP3446700A1
(en)
|
2012-10-30 |
2019-02-27 |
Bioverativ Therapeutics Inc. |
Methods of using fviii polypeptide
|
|
SI3889173T1
(sl)
|
2013-02-15 |
2023-11-30 |
Bioverativ Therapeutics Inc. |
Optimiran gen dejavnika VIII
|
|
AR095527A1
(es)
|
2013-03-15 |
2015-10-21 |
Biogen Idec Inc |
Formulaciones de polipéptido fc-factor ix
|
|
DK2968477T3
(da)
|
2013-03-15 |
2020-03-09 |
Bioverativ Therapeutics Inc |
Faktor viii-polypeptidformuleringer
|
|
SG10201710616XA
(en)
|
2013-06-28 |
2018-02-27 |
Biogen Ma Inc |
Thrombin cleavable linker with xten and its uses thereof
|
|
WO2015021423A2
(en)
|
2013-08-08 |
2015-02-12 |
Biogen Idec Ma Inc. |
Purification of chimeric fviii molecules
|
|
US10548953B2
(en)
|
2013-08-14 |
2020-02-04 |
Bioverativ Therapeutics Inc. |
Factor VIII-XTEN fusions and uses thereof
|
|
US10584147B2
(en)
|
2013-11-08 |
2020-03-10 |
Biovertiv Therapeutics Inc. |
Procoagulant fusion compound
|
|
US10325687B2
(en)
|
2013-12-06 |
2019-06-18 |
Bioverativ Therapeutics Inc. |
Population pharmacokinetics tools and uses thereof
|
|
AU2015204646B2
(en)
|
2014-01-10 |
2020-08-27 |
Bioverativ Therapeutics Inc. |
Factor VIII chimeric proteins and uses thereof
|
|
KR102382402B1
(ko)
|
2014-02-04 |
2022-04-01 |
바이오젠 엠에이 인코포레이티드 |
번역 후 변형을 강화시키기 위한 통류 방식 양이온 교환 크로마토그래피의 용도
|
|
EP3160478A4
(en)
|
2014-06-30 |
2018-05-16 |
Bioverativ Therapeutics Inc. |
Optimized factor ix gene
|
|
MA40864A
(fr)
|
2014-10-31 |
2017-09-05 |
Biogen Ma Inc |
Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
|
|
CN104630131B
(zh)
*
|
2015-01-15 |
2017-08-15 |
上海交通大学 |
一种稳定表达人凝血八因子的cho细胞株及其应用
|
|
BR112018002150A2
(pt)
|
2015-08-03 |
2018-09-18 |
Bioverativ Therapeutics Inc |
proteínas de fusão do fator ix e métodos de fabricação e uso das mesmas
|
|
WO2017136358A1
(en)
|
2016-02-01 |
2017-08-10 |
Bioverativ Therapeutics Inc. |
Optimized factor viii genes
|
|
CN110520149A
(zh)
|
2016-12-02 |
2019-11-29 |
比奥维拉迪维治疗股份有限公司 |
诱导对凝血因子的免疫耐受性的方法
|
|
IL319473A
(en)
|
2016-12-02 |
2025-05-01 |
Bioverativ Therapeutics Inc |
Methods for treating hemophilic arthritis using chimeric blood clotting factors
|
|
TW202545984A
(zh)
|
2017-08-09 |
2025-12-01 |
美商生物化學醫療公司 |
核酸分子及其用途
|
|
WO2019067766A1
(en)
|
2017-09-27 |
2019-04-04 |
Sigilon Therapeutics, Inc. |
METHODS, COMPOSITIONS AND IMPLANTABLE ELEMENTS COMPRISING ACTIVE CELLS
|
|
AU2019215063B2
(en)
|
2018-02-01 |
2025-10-16 |
Bioverativ Therapeutics, Inc. |
Use of lentiviral vectors expressing Factor VIII
|
|
IL312315A
(en)
|
2018-04-04 |
2024-06-01 |
Sigilon Therapeutics Inc |
Implantable particles and related methods
|
|
WO2019195056A1
(en)
|
2018-04-04 |
2019-10-10 |
Sigilon Therapeutics, Inc. |
Methods, compositions, and implantable elements comprising stem cells
|
|
BR112020022164A2
(pt)
|
2018-05-18 |
2021-02-02 |
Bioverativ Therapeutics Inc. |
métodos de tratamento de hemofilia a
|
|
WO2020033863A1
(en)
|
2018-08-09 |
2020-02-13 |
Bioverativ Therapeutics Inc. |
Nucleic acid molecules and uses thereof for non-viral gene therapy
|
|
UY38389A
(es)
|
2018-09-27 |
2020-04-30 |
Sigilon Therapeutics Inc |
Dispositivos implantables para terapia celular y métodos relacionados
|
|
US10654911B1
(en)
*
|
2019-04-02 |
2020-05-19 |
Beijing Neoletix Biological Technology Co., Ltd. |
Vector co-expressing truncated von Willebrand factor and factor VIII
|
|
US20220233650A1
(en)
|
2019-06-19 |
2022-07-28 |
Bioverativ Therapeutics Inc. |
Recombinant factor viii-fc for treating hemophilia and low bone mineral density
|
|
JP7803014B2
(ja)
|
2019-09-30 |
2026-01-21 |
バイオベラティブ セラピューティクス インコーポレイテッド |
レンチウイルスベクター製剤
|
|
US12173307B2
(en)
|
2020-06-24 |
2024-12-24 |
Bioverativ Therapeutics Inc. |
Methods for the purification of viral vectors
|
|
CA3229323A1
(en)
|
2021-08-23 |
2023-03-02 |
Ajay MAGHODIA |
Optimized factor viii genes
|
|
CA3232988A1
(en)
|
2021-09-30 |
2023-04-06 |
Bioverativ Therapeutics Inc. |
Nucleic acids encoding factor viii polypeptides with reduced immunogenicity
|
|
JP2025534667A
(ja)
|
2022-10-11 |
2025-10-17 |
シギロン セラピューティクス, インコーポレイテッド |
疾患治療のための改変細胞及び移植可能エレメント
|
|
EP4602155A1
(en)
|
2022-10-11 |
2025-08-20 |
Sigilon Therapeutics, Inc. |
Engineered cells and implantable elements for treatment of disease
|